Pomalidomide in combination with dexamethasone approved for use in refractory multiple myeloma

被引：0
|
作者：
Brown, Emily
机构：
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2013年 / 2卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：516 / 517
页数：2
相关论文
共 50 条
  • [31] Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Yee, Andrew
    Laubach, Jacob
    Nooka, Ajay
    O'Donnell, Elizabeth
    Harrington, Cynthia
    Agyemang, Emerentia
    Burke, Jill
    Gammon, Marilyn
    Lively, Kathleen
    Packer, Lisette
    Bishop, James
    Bernstein, Zachary
    Lyons, Rebecca
    Wright, Alexandra
    McVey, Cailin
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S58 - S59
  • [32] Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
    Cinnie Yentia Soekojo
    Kihyun Kim
    Shang-Yi Huang
    Chor-Sang Chim
    Naoki Takezako
    Hideki Asaoku
    Hideo Kimura
    Hiroshi Kosugi
    Junichi Sakamoto
    Sathish Kumar Gopalakrishnan
    Chandramouli Nagarajan
    Yuan Wei
    Rajesh Moorakonda
    Shu Ling Lee
    Je Jung Lee
    Sung-Soo Yoon
    Jin Seok Kim
    Chang Ki Min
    Jae-Hoon Lee
    Brian Durie
    Wee Joo Chng
    Blood Cancer Journal, 9
  • [33] AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Potluri, R.
    Chen, C.
    Ranjan, S.
    Kumar, A.
    Bhandari, H.
    Davis, C.
    VALUE IN HEALTH, 2019, 22 : S104 - S104
  • [34] Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis
    Farrell, James
    Bertin, Nicolas
    Fischer, Claire
    Gauthier, Aline
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S169 - S170
  • [35] Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network
    Soekojo, Cinnie Yentia
    Kim, Kihyun
    Huang, Shang-Yi
    Chim, Chor-Sang
    Takezako, Naoki
    Asaoku, Hideki
    Kimura, Hideo
    Kosugi, Hiroshi
    Sakamoto, Junichi
    Gopalakrishnan, Sathish Kumar
    Nagarajan, Chandramouli
    Wei, Yuan
    Moorakonda, Rajesh
    Lee, Shu Ling
    Lee, Je Jung
    Yoon, Sung-Soo
    Kim, Jin Seok
    Min, Chang Ki
    Lee, Jae-Hoon
    Durie, Brian
    Chng, Wee Joo
    BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [36] Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
    Trudel, Suzanne
    McCurdy, Arleigh
    Fu, Molei
    Sutherland, Heather J.
    Louzada, Martha L.
    Chu, Michael P.
    White, Darrell J.
    Mian, Hira S.
    Kotb, Rami
    Othman, Ibraheem
    Kardjadj, Moustafa
    Gul, Engin
    Reece, Donna E.
    BLOOD, 2022, 140 : 7306 - 7307
  • [37] Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Campana, Frank
    Gao, Lei
    Dubin, Franck
    Wack, Claudine
    Anderson, Kenneth C.
    BLOOD, 2016, 128 (22)
  • [38] A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma
    Rosenzweig, Michael
    Sanchez, James
    Chowdhury, Arnab
    Nathwani, Nitya
    Janakiram, Murali
    Htut, Myo
    Sahebi, Firoozeh
    Walker, Tricia
    Pichiorri, Flavia
    Palmer, Joycelynne
    Krishnan, Amrita
    Keats, Jonathan
    Rosen, Steven
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S153 - S153
  • [39] Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone
    Hagiwara, May
    Panjabi, Sumeet
    Sharma, Arati
    Delea, Thomas E.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 818 - 829
  • [40] Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Htut, Myo
    Gasparetto, Cristina
    Zonder, Jeffrey A.
    Martin, Thomas G., III
    Chen, Janice
    Brooks, Christopher
    McDonald, Peter
    Rupprecht, Nicole
    Wysowskyj, Halyna
    Chauhan, Dharminder
    Ray, Arghya
    Anderson, Kenneth C.
    Paba-Prada, Claudia E.
    BLOOD, 2019, 134
12345